| 前收市價 | 573.34 |
| 開市 | 570.22 |
| 買盤 | 224.60 x 900 |
| 賣出價 | 659.00 x 800 |
| 今日波幅 | 557.90 - 577.17 |
| 52 週波幅 | 492.84 - 654.62 |
| 成交量 | |
| 平均成交量 | 83,833 |
| 市值 | 8.483B |
| Beta 值 (5 年，每月) | 0.42 |
| 市盈率 (最近 12 個月) | 30.11 |
| 每股盈利 (最近 12 個月) | 18.61 |
| 業績公佈日 | 2024年7月24日 - 2024年7月29日 |
| 遠期股息及收益率 | 1.60 (0.29%) |
| 除息日 | 2024年2月23日 |
| 1 年預測目標價 | 690.00 |
ZacksChemed (CHE) Lags Q1 Earnings Estimates, Reaffirms 2024 View
Chemed's (CHE) first-quarter 2024 results reflect VITAS' impressive revenue growth and improved average revenues per patient per day.
ZacksChemed (CHE) Q1 Earnings Miss Estimates
Chemed (CHE) delivered earnings and revenue surprises of -4.94% and 0.35%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ZacksHere's Why You Should Retain Chemed (CHE) Stock for Now
Investors are optimistic about Chemed (CHE), backed by the strong performance of the VITAS Healthcare and Roto-Rooter segments.
